SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* BEIER THOMAS E (Last) (First) (Middle) 4400 BISCAYNE BLVD (Street) MIAMI FL 33137-3227 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol IVAX CORP [ IVX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Senior Vice President and CFO
	3. Date of Earliest Transaction (Month/Day/Year) 01/26/2006
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.10 Par Value Per Share	01/26/2006		D		87,891	D	(1)	0	I(1)	Trust
Common Stock, $.10 Par Value Per Share	01/26/2006		D		3,974	D	(2)	0	I(2)	ESPP
Common Stock, $.10 Par Value Per Share	01/26/2006		D		702	D	(3)	0	I(3)	IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$11.7	01/26/2006		D			35,156	(4)	01/12/2010	Common Stock	35,156	$0	0	D
Employee Stock Option (Right to Buy)	$20.79	01/26/2006		D			31,250	(5)	01/21/2011	Common Stock	31,250	$0	0	D
Employee Stock Option (Right to Buy)	$15.43	01/26/2006		D			25,000	(6)	01/21/2012	Common Stock	25,000	$0	0	D
Employee Stock Option (Right to Buy)	$8.79	01/26/2006		D			50,000	(7)	03/05/2013	Common Stock	50,000	$0	0	D
Employee Stock Option (Right to Buy)	$18.4	01/26/2006		D			15,000	(8)	03/14/2014	Common Stock	15,000	$0	0	D
Employee Stock Option (Right to Buy)	$18.4	01/26/2006		D			50,000	(9)	03/14/2014	Common Stock	50,000	$0	0	D
Employee Stock Option (Right to Buy)	$15.93	01/26/2006		D			10,000	(10)	02/22/2010	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. Held by the Thomas E. Beier and Evelyn M. Beier Trustee FBO Thomas E. Beier Trust. Disposed of pursuant to merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 37,226 shares of Teva Common Stock, having a market value of $40.63 per share on the effective date of the merger and cash in the amount of $1,142,583 subject to pro-ration.

2. Held in the IVAX Employee Stock Purchase Plan. Disposed of pursuant to merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 1,683 shares of Teva Common Stock, having a market value of $40.63 per share on the effective date of the merger and cash in the amount of $51,662 subject to pro-ration.

3. Held in a Self Employment Retirement Plan. Disposed of pursuant to merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 297 shares of Teva Common Stock, having a market value of $40.63 per share on the effective date of the merger and cash in the amount of $9,126 subject to pro-ration.

4. This option, which provided for vesting in four equal annual installments beginning January 13, 2000, was assumed by Teva in the merger and replaced with an option to purchase 29,780 shares of Teva Common Stock for $13.81 per share.

5. This option, which provided for vesting in four equal annual installments beginning January 22, 2001, was assumed by Teva in the merger and replaced with an option to purchase 26,471 shares of Teva Common Stock for $24.54 per share.

6. This option, which provided for vesting in four equal annual installments beginning January 22, 2002, was assumed by Teva in the merger and replaced with an option to purchase 21,177 shares of Teva Common Stock for 18.22 per share.

7. This option, which provided for vesting in four equal annual installments beginning March 6, 2003, was assumed by Teva in the merger and replaced with an option to purchase 42,355 shares of Teva Common Stock for $10.38 per share.

8. This option, which provided for vesting in four equal annual installments beginning March 15, 2004, was assumed by Teva in the merger and replaced with an option to purchase 12,706 shares of Teva Common Stock for $21.72 per share.

9. This option, which provided for vesting in four equal annual installments beginning March 15, 2004, was assumed by Teva in the merger and replaced with an option to purchase 42,355 shares of Teva Common Stock for $21.72 per share.

10. This option, which provided for vesting in four equal annual installments beginning February 23, 2005, was assumed by Teva in the merger and replaced with an option to purchase 8,471 shares of Teva Common Stock for $18.81 per share.

	/s/ Thomas E. Beier	01/26/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.